FORMULATION AND IN VITRO EVALUATION OF MATRIX TABLETS OF METOCLOPRAMIDE HYDROCHLORIDE

S. JAYA*, DIVYA. S

Department of Pharmaceutics, Anurag Pharmacy College, Ananthagiri, Kodad, Suryapet 502806, Telangana, India
Email: jayamay24@gmail.com
Received: 27 Oct 2018, Revised and Accepted: 19 Nov 2018

ABSTRACT

Objective: The purpose of present study was to formulate oral sustained release matrix tablet of metoclopramide hydrochloride and to evaluate the effect of varying concentrations of hydrophobic and hydrophilic polymers on drug release.

Methods: Drug-excipients compatibility studies were carried out by using Fourier transform infrared spectroscopy (FTIR). The matrix tablets were prepared by direct compression technique using Xanthan gum and ethyl cellulose alone and in combination as release retardant. Dicalcium phosphate was used as diluent. The prepared matrix tablets were evaluated for their physicochemical parameters such as weight variation, hardness, friability, content uniformity and in vitro drug release studies were performed using USP-type II (paddle) dissolution apparatus.

Results: Pre and post compression parameters were evaluated and all the parameters were found within the limit. The matrix tablets prepared with xanthan gum and combination of xanthan gum and ethyl cellulose were retarded the drug release upto 12 h. Ethyl cellulose alone could not control the drug release for 12 h. The Formulation with drug to xanthan gum (1:1.5), released 97.62 % of drug in 12 h. The kinetic treatment showed that the release of drug follows zero order kinetics (R²=0.985). Korsmeyer and Peppas equation values of n were found to be in the range of 0.40-0.56, indicating that the drug release mechanism was diffusion.

Conclusion: Matrix tablet is the simple, efficient and economic method to sustain the release of metoclopramide to prevent extrapyramidal side effects.

Keywords: Matrix tablets, Metoclopramide hydrochloride, Xanthan gum

INTRODUCTION

Metoclopramide hydrochloride is a potent antiemetic drug used to treat emesis caused due to chemotherapy in cancer patients [1]. Metoclopramide is 4-amino-5-chloro-N-[2-(diethyl amino) ethyl]methyleneamino) benzamide mono hydrochloride mono hydrate. It antagonizes D₂ dopamine receptors in chemoreceptor trigger zone (CTZ) of the medulla. It exerts gastroprokinetic (increases motility of the stomach and duodenum) effect by antagonizing dopamine mediated relaxation effect on gastro intestinal smooth muscle results to an increase of gastric empting into the intestine there by preventing nausea and vomiting. Metoclopramide hydrochloride is a freely soluble drug and is rapidly absorbed from the gastrointestinal tract [2,3]. It has short and variable biological half-life i.e. 5±1 hr [4]. It is usually administered in per oral dose of 10-15 mg four times a day. This frequent administration results blood level fluctuations leads to extrapyramidal symptoms [5].

Oral administration is the most common and preferred route for delivery of most therapeutic agents. The popularity of oral route is attributed to ease of administration, accurate dosing, cost effective, flexibility in design of dosage form and high patient compliance. Sustained release dosage forms are designed to release the drug at a slow rate by maintaining a constant drug level in blood for a specified period of time with minimum side effects, optimized therapy and better patient compliance. Matrix technologies have often proven popular among the oral controlled drug delivery systems and improve the patient compliance. The probable additive effect of mixture of xanthan gum and ethyl cellulose on retarding drug release was also studied.

MATERIALS AND METHODS

Materials

Metoclopramide hydrochloride was purchased from Yarrow chemical Ltd., Mumbai (India). Xanthan gum, ethyl cellulose, dicalcium phosphate, magnesium stearate and talc were purchased from Aman scientific traders Vijayawada (India). All other reagents used were of analytical grade.

Methods

Analytical method for calibration curve of metoclopramide hydrochloride

Maximum wavelength of metoclopramide hydrochloride was found to be 272 nm using UV-visible spectroscopy. Standard solution (100µg/ml) was prepared from stock solution (1 mg/ml) with pH 6.8 phosphate buffer. Aliquots of standard drug solution ranging from 0.4 to 2.4 ml were transferred into 10 ml volumetric flask and were diluted up to the mark with pH 6.8 phosphate buffer. The absorbance of each solution was measured at 272 nm against pH 6.8 phosphate buffer. A plot of concentration of drug versus absorbance was plotted. The linear regression analysis was applied. The standard regression equation for metoclopramide hydrochloride obtained was y = 0.037x+0.003 with a coefficient of regression (R²) of 0.999.
Drug-excipient compatibility study
Compatibility study of metoclopramide hydrochloride with the excipients was determined by Fourier transform infrared (FTIR) spectroscopy.

Formulation design
Dose calculation of the sustained release formulation [11]

Total dose = usual dose (D) + maintenance dose (Dm)

Pharmacokinetic studies showed that a dose of 10 mg of metoclopramide hydrochloride produces an effective blood level concentration within 0.5 h with the mean half-life of 4 h. The elimination rate constant

\[ = 0.1732 \text{ h}^{-1} \]

The available rate \( R = k \times D \)

Where, \( D \) is the usual dose of the drug.

But \( D \) is corrected = \( D - (R \times t_p) \)

\[ = 9.134 + 20.784 = 29.918 \text{ mg} \]

Where, \( t_p \) is the time period required to achieve a peak plasma concentration.

Preparation of matrix tablets
Matrix tablets of metoclopramide hydrochloride were prepared by direct compression technique. All the ingredients were individually screened through sieve no. 60, except glidant and lubricant. Required quantities of metoclopramide hydrochloride, polymer, diluent were accurately weighed according to the composition shown in table 1 and mixed in a polybag for about 30 to 45 min. The obtained blend was lubricated with talc and magnesium stearate for another 5 min and then the resultant mixture was directly compressed into tablets with 8 mm dome-shaped punches using 12-station rotary tablet machine (CEMACH, Ahmedabad, India). The final weight of the tablet was adjusted to 250 mg.

Table 1: Composition of matrix tablets of metoclopramide hydrochloride

<table>
<thead>
<tr>
<th>Ingredients per tablets (mg)</th>
<th>Composition (mgs) of the prepared formulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>F2</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>30</td>
</tr>
<tr>
<td>Xanthan gum (XG)</td>
<td>30</td>
</tr>
<tr>
<td>Ethyl cellulose (EC)</td>
<td>-</td>
</tr>
<tr>
<td>XG+EC</td>
<td>-</td>
</tr>
<tr>
<td>Di calcium phosphate</td>
<td>180</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>5</td>
</tr>
<tr>
<td>Talc</td>
<td>5</td>
</tr>
<tr>
<td>Tablet weight</td>
<td>250</td>
</tr>
</tbody>
</table>

Micromeritic properties of the blended powder

Angle of repose
The angle of repose of powder blend was determined by the fixed funnel method. The accurately weighed powder was taken in a funnel. The height of the funnel was adjusted in such a way that the tip of the funnel just touched the apex of the heap of the powder. The powder was allowed to flow through the funnel freely onto the surface. The diameter of the powder cone was measured and the angle of repose was calculated using the following equation [12].

\[ \tan \theta = \frac{h}{r} \]

Where, \( \theta \) = angle of repose, \( h \) = height of the pile, \( r \) = radius of the pile base

Bulk density and tapped density
A quantity of 2 g of powder from each formula, previously lightly shaken to break any agglomerates formed was introduced into a 10 ml measuring cylinder. After the initial volume was observed then calculate bulk density using the following formula [12].

Bulk density = \[ \frac{\text{weight of the powder}}{\text{bulk volume}} \]

The cylinder was allowed to fall under its own weight onto a hard surface from the height of 2.5 cm at 2-second intervals. The tapping was continued until no further change in volume was noted. Tapped density was calculated using the following formula [12].

Tapped density = \[ \frac{\text{weight of the powder}}{\text{tapped volume}} \]

Compressibility index
The compressibility index of the powder blend was determined by Carr’s compressibility index [12].

\[ \text{Carr’s index} = \frac{\text{tapped density} - \text{bulk density}}{\text{tapped density}} \times 100 \]

Evaluation of matrix tablets
The tablets were evaluated for their physical properties like weight variation, hardness, and friability.

Weight variation
20 tablets of each formulation were weighed using an electronic weighing balance. The average weight was calculated and individual tablet weight was compared with average weight [12].

Hardness and friability
The hardness of three tablets was measured by Monsanto hardness tester. Hardness of tablets was measured in terms of kg/cm². Friability of tablets was measured by using Roche friabilator. Ten tablets were accurately weighed and placed in the friabilator and operated for 100 revolutions. The tablets were dedusted and reweighed and friability was calculated using the following equation [14].

\[ \text{Friability} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100 \]

Uniformity of drug content
10 Tablets were weighed from each formulation and triturated in the mortar to a fine powder. Powder equivalent to 30 mg of metoclopramide was extracted in 100 ml of pH 6.8 phosphate buffer and the liquid was filtered. The drug content was determined by measuring the absorbance at 272 nm (using UV–Visible spectrophotometer, Lab India) after appropriate dilution with pH 6.8 phosphate buffer. The drug content was determined by calibration curve.
In vitro dissolution study

The in vitro dissolution study of matrix tablets of metoclopramide was performed using USP type II (paddle) dissolution apparatus (BDK) at a rotational speed of 50 rpm. In order to simulate gastrointestinal transit conditions, the tablets were subjected to different dissolution media. The dissolution medium consisted of 900 ml of p<sub>H</sub> 1.2 buffer for the first two hours and p<sub>H</sub> 6.8 phosphate buffer for the next ten hours. The dissolution medium was maintained at a temperature of 37±0.5 °C. At predetermined time intervals, 5 ml sample of the solution was withdrawn from the dissolution apparatus and the samples were replaced with fresh dissolution medium. The collected samples were filtered through a 0.45 μm membrane filter and diluted to a suitable concentration with p<sub>H</sub> 6.8 phosphate buffer. An absorbance of these solutions was measured at 272 nm. Cumulative percentage of drug release was calculated using equation obtained from a calibration curve [15].

Kinetic analysis of drug release data

The drug release data was fitted to zero order and first order to know the order of reaction. To study the mechanism of drug release from the formulations the release data were fitted to the following equations:

- **Higuchi model:** \( Q/Q_t = Kt^n \)
- **Korsmeyer–Peppas model:** \( Q/Q_t = Kt^n \)

Where \( Q \) is amount of drug release at time \( t \), \( Q_t \) is the total amount of drug release and \( n \) is the diffusional exponent that characterizes the mechanism of drug release. The values of the coefficient were calculated using the regression analysis between log \( Q/Q_t \) and log time. The diffusional exponent \( n \) value was obtained from the slope of the regression equation and \( K \) was calculated from antilog of the intercept value.

If the value of \( n \) for a cylinder is<0.45 it suggests the Fickian release (diffusion controlled), if \( n >0.45 \) and<0.89 it is non-Fickian release (diffusion and polymer relaxation), 0.89 is case II release (only relaxation and swelling) and>0.89 it suggests super case II release (relaxation and erosion) for swellable systems.

**RESULTS AND DISCUSSION**

Powder characterization

The powder mixture of all the formulations were evaluated for angle of repose, bulk density, tapped density, compressibility index, and their values were shown in table 2. Angle of repose and compressibility index for all the formulations were found to be less than 30 ° and less than 17.13 %, indicated that powder mixture has good flow properties.

**Evaluation of physical parameters**

Sustained release matrix tablets of metoclopramide hydrochloride and their mixture-xanthan gum plus ethyl cellulose (F7,F8,F9) and the physical properties of metoclopramide matrix tablets were found to be in the range of 5.05±0.15 to 5.87±0.08 kg/cm<sup>2</sup>. The hardness of the tablets was measured by double beam UV spectrophotometer (LABINDIA). The content of metoclopramide hydrochloride was found to be in the range of 98.33 to 99.98%.

**In vitro dissolution study**

Metoclopramide release from the matrix tablets was studied for the first two hours in p<sub>H</sub> 1.2 buffer and the next ten hours in p<sub>H</sub> 6.8 phosphate buffer. Total nine formulations were made with xanthan gum, ethyl cellulose and combination of xanthan gum and ethyl cellulose in different ratios i.e 1:1, 1:1.5 and 1:2. The release profiles are given in fig. 1.
ingredient through capillaries. Xanthan gum could control the release of metoclopramide hydrochloride up to 12 h because of its high molecular weight. These results indicate that xanthan gum has a higher drug retarding ability than ethyl cellulose. Presence of xanthan gum alone and in combination retarded the initial release of drug from the tablets due to high swelling.

The release data of matrix tablets were fitted into various mathematical models (zero order, first order, higuchi, and Peppas) to evaluate the kinetics and mechanism of drug release from the tablets. The model that best fits the release data is selected based on the correlation coefficient value in various models. The model that gives high $R^2$ value considered as the best fit of the release data. The $R^2$ values in zero, first order, higuchi peppas, and hixon-crowel models are given in table 4.

### Table 4: Release kinetics of metoclopramide hydrochloride matrix tablets

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Zero-order</th>
<th>First order</th>
<th>Higuchi</th>
<th>Peppas</th>
<th>Hixon-crowel</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.894</td>
<td>0.975</td>
<td>0.989</td>
<td>0.989</td>
<td>0.883</td>
</tr>
<tr>
<td>F2</td>
<td>0.923</td>
<td>0.897</td>
<td>0.993</td>
<td>0.991</td>
<td>0.52</td>
</tr>
<tr>
<td>F3</td>
<td>0.963</td>
<td>0.985</td>
<td>0.987</td>
<td>0.990</td>
<td>0.56</td>
</tr>
<tr>
<td>F4</td>
<td>0.853</td>
<td>0.946</td>
<td>0.992</td>
<td>0.999</td>
<td>0.40</td>
</tr>
<tr>
<td>F5</td>
<td>0.888</td>
<td>0.973</td>
<td>0.986</td>
<td>0.982</td>
<td>0.40</td>
</tr>
<tr>
<td>F6</td>
<td>0.920</td>
<td>0.860</td>
<td>0.988</td>
<td>0.981</td>
<td>0.46</td>
</tr>
<tr>
<td>F7</td>
<td>0.945</td>
<td>0.847</td>
<td>0.993</td>
<td>0.986</td>
<td>0.53</td>
</tr>
<tr>
<td>F8</td>
<td>0.918</td>
<td>0.872</td>
<td>0.994</td>
<td>0.995</td>
<td>0.48</td>
</tr>
<tr>
<td>F9</td>
<td>0.927</td>
<td>0.904</td>
<td>0.995</td>
<td>0.996</td>
<td>0.50</td>
</tr>
</tbody>
</table>

The results given in table 3 indicated that the drug release from the matrix tablets followed zero order kinetics. To evaluate the drug release mechanism from the matrix tablets plots of percent drug released versus square root of time as per Higuchi’s equation were constructed. These plots were found to be linear with all the tablets with correlation coefficient values in the range 0.986 to 0.995 indicating that the drug release from the tablet was diffusion controlled. When the release data were analyzed as per peppas equation, the release exponent $n$ value was less than 0.89 with all the tablets indicating Fickian diffusion might be the mechanism for the drug release from the matrix tablets.

### Compatibility studies

From the FTIR studies shown in fig 2, it is very clear that there are no interactions between drug and excipients. All the peaks responsible for the active functional groups were present in the best formulation (F2). The characteristic and observed peaks are mentioned in table 5.

Fig. 2(a): FTIR spectrum of pure metoclopramide hydrochloride
CONCLUSION
Sustained release matrix tablets of metoclopramide hydrochloride were prepared using different ratios of xanthan gum and ethyl cellulose by direct compression method. The results of the present study demonstrate that the ethyl cellulose alone could not control the metoclopramide release effectively for 12 h, whereas when combined with xanthan gum, it could control the release of metoclopramide from their matrices. It is concluded that the sustained release of metoclopramide hydrochloride over a period of 12 h was obtained with formulation (F-2) containing xanthan gum. The mechanism of drug release from the matrix tablets was found to be diffusion controlled i.e. fickian diffusion. Sustained release matrix tablets of metoclopramide hydrochloride can be expected to reduce the frequency of administration and decrease the dose-dependent side effects associated with repeated administration of conventional metoclopramide hydrochloride tablets.

ACKNOWLEDGMENT
The authors are thankful to the principal and management of Anurag Pharmacy College, for providing necessary facilities to carry out this work.

AUTHORS CONTRIBUTIONS
All the authors have contributed equally

CONFLICT OF INTERESTS
Declared none

REFERENCES

Table 5: Data of FT-IR spectra of pure and best formulation

<table>
<thead>
<tr>
<th>Functional group</th>
<th>Characteristic peak cm⁻¹</th>
<th>Observed peaks-pure drug cm⁻¹</th>
<th>Observed peaks-best formulation cm⁻¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-H (stretching)</td>
<td>3500 [asymmetric]</td>
<td>3463</td>
<td>3484</td>
</tr>
<tr>
<td></td>
<td>3400 [symmetric]</td>
<td>3396</td>
<td>3396</td>
</tr>
<tr>
<td>OCH₂</td>
<td>1270-1230</td>
<td>1269</td>
<td>1266</td>
</tr>
<tr>
<td>N-H (bending)</td>
<td>1650-1580</td>
<td>1596</td>
<td>1645</td>
</tr>
<tr>
<td>C-N (stretching)</td>
<td>1220-1020</td>
<td>1215</td>
<td>1211</td>
</tr>
<tr>
<td>C≡C</td>
<td>1500</td>
<td>1501</td>
<td>1502</td>
</tr>
</tbody>
</table>

Fig. 2(b): FTIR spectrum of metoclopramide hydrochloride matrix tablet (F2)